Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-5-13
pubmed:abstractText
Over the past few years, technological procedures have been developed for utilizing stem cells in transplantation medicine. Human embryonic stem (ES) cells can produce an unlimited number of differentiated cells and are, therefore, considered a potential source of cellular material for use in transplantation medicine. However, serious clinical problems can arise when uncontrolled cell proliferation occurs following transplantation. To avoid these potential problems, we genetically engineered human ES cell lines to express the herpes simplex virus thymidine kinase (HSV-tk) gene. Expression of the HSV-tk protein renders the ES cells sensitive to the U.S. Food and Drug Administration-approved drug ganciclovir, inducing destruction of HSV-tk(+) cells at ganciclovir concentrations that are nonlethal to other cell types. The reversion rate of engineered cells was low even under prolonged selection with ganciclovir. The HSV-tk(+) clones retained a normal karyotype and the ability to differentiate to cells from all three germ layers. Most importantly, tumors that arose in mice following subcutaneous injection of HSV-tk(+) human ES cells could be ablated in vivo by administration of ganciclovir. By utilizing these cell lines, safety levels can be improved in transplantations involving tissues derived from human ES cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1066-5099
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
257-65
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12743320-Animals, pubmed-meshheading:12743320-Antiviral Agents, pubmed-meshheading:12743320-Cell Culture Techniques, pubmed-meshheading:12743320-Cell Death, pubmed-meshheading:12743320-Cell Differentiation, pubmed-meshheading:12743320-Cell Division, pubmed-meshheading:12743320-Cell Transformation, Neoplastic, pubmed-meshheading:12743320-Cells, Cultured, pubmed-meshheading:12743320-Clone Cells, pubmed-meshheading:12743320-Disease Models, Animal, pubmed-meshheading:12743320-Drug Resistance, pubmed-meshheading:12743320-Ganciclovir, pubmed-meshheading:12743320-Genes, Transgenic, Suicide, pubmed-meshheading:12743320-Genetic Engineering, pubmed-meshheading:12743320-Genetic Markers, pubmed-meshheading:12743320-Humans, pubmed-meshheading:12743320-Karyotyping, pubmed-meshheading:12743320-Mice, pubmed-meshheading:12743320-Mice, SCID, pubmed-meshheading:12743320-Neoplasms, pubmed-meshheading:12743320-Pluripotent Stem Cells, pubmed-meshheading:12743320-Stem Cell Transplantation, pubmed-meshheading:12743320-Thymidine Kinase, pubmed-meshheading:12743320-Viral Proteins
pubmed:year
2003
pubmed:articleTitle
Selective ablation of human embryonic stem cells expressing a "suicide" gene.
pubmed:affiliation
Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't